| Duangnapa S Cuddy, DO | |
|
550 S Landmark Ave, Bloomington, IN 47403 | |
| (812) 355-6900 | |
| Not Available |
| Full Name | Duangnapa S Cuddy |
|---|---|
| Gender | Female |
| Speciality | Vascular Surgery |
| Experience | 18 Years |
| Location | 550 S Landmark Ave, Bloomington, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053515429 | NPI | - | NPPES |
| 2903 | Other | WV | WV LICENSE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health Bloomington Hospital | Bloomington, IN | Hospital |
| Indiana University Health Bedford Hospital | Bedford, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Indiana University Health Southern Indiana Physicians Llc | 6204748197 | 449 |
News Archive
Israel Shippy doesn't remember much about having COVID-19 — or the unusual auto-immune disease it triggered — other than being groggy and uncomfortable for a bunch of days. He's a 5-year-old, and would much rather talk about cartoons, or the ideas for inventions that constantly pop into his head.
Three years ago Mark Kay, MD, PhD, published the first results showing that a biological phenomenon called RNA interference could be an effective gene therapy technique. Since then he has used RNAi gene therapy to effectively shut down the viruses that cause hepatitis and HIV in mice.
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.
Writing in the Huffington Post's "Global Motherhood" blog, Chip Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation, highlights the foundation's "first annual 'Global Champions for a Mother's Fight' gala, an opportunity to honor some of our heroes in the battle against pediatric HIV/AIDS and discuss global change, innovation, and advocacy."
Researchers from the Genes and Cancer research group at the Bellvitge Biomedical Research Institute have identified inactivating mutations in a number of genes that code for HLA-I histocompatibility complex proteins, which are involved in the immune response and can condition the tesponse of lung cancer patients to immunotherapy.
› Verified 5 days ago
| Entity Name | Indiana University Health Southern Indiana Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013953983 PECOS PAC ID: 6204748197 Enrollment ID: O20040423000556 |
News Archive
Israel Shippy doesn't remember much about having COVID-19 — or the unusual auto-immune disease it triggered — other than being groggy and uncomfortable for a bunch of days. He's a 5-year-old, and would much rather talk about cartoons, or the ideas for inventions that constantly pop into his head.
Three years ago Mark Kay, MD, PhD, published the first results showing that a biological phenomenon called RNA interference could be an effective gene therapy technique. Since then he has used RNAi gene therapy to effectively shut down the viruses that cause hepatitis and HIV in mice.
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.
Writing in the Huffington Post's "Global Motherhood" blog, Chip Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation, highlights the foundation's "first annual 'Global Champions for a Mother's Fight' gala, an opportunity to honor some of our heroes in the battle against pediatric HIV/AIDS and discuss global change, innovation, and advocacy."
Researchers from the Genes and Cancer research group at the Bellvitge Biomedical Research Institute have identified inactivating mutations in a number of genes that code for HLA-I histocompatibility complex proteins, which are involved in the immune response and can condition the tesponse of lung cancer patients to immunotherapy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Duangnapa S Cuddy, DO 550 S Landmark Ave, Bloomington, IN 47403-3239 Ph: (812) 355-6900 | Duangnapa S Cuddy, DO 550 S Landmark Ave, Bloomington, IN 47403 Ph: (812) 355-6900 |
News Archive
Israel Shippy doesn't remember much about having COVID-19 — or the unusual auto-immune disease it triggered — other than being groggy and uncomfortable for a bunch of days. He's a 5-year-old, and would much rather talk about cartoons, or the ideas for inventions that constantly pop into his head.
Three years ago Mark Kay, MD, PhD, published the first results showing that a biological phenomenon called RNA interference could be an effective gene therapy technique. Since then he has used RNAi gene therapy to effectively shut down the viruses that cause hepatitis and HIV in mice.
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.
Writing in the Huffington Post's "Global Motherhood" blog, Chip Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation, highlights the foundation's "first annual 'Global Champions for a Mother's Fight' gala, an opportunity to honor some of our heroes in the battle against pediatric HIV/AIDS and discuss global change, innovation, and advocacy."
Researchers from the Genes and Cancer research group at the Bellvitge Biomedical Research Institute have identified inactivating mutations in a number of genes that code for HLA-I histocompatibility complex proteins, which are involved in the immune response and can condition the tesponse of lung cancer patients to immunotherapy.
› Verified 5 days ago
Terrence M Greene, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 419 W 1st St, Bloomington, IN 47403 Phone: 812-336-7879 Fax: 812-336-7881 | |
Dr. Luke Portwood Fife, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 550 S Landmark Ave, Bloomington, IN 47403 Phone: 812-355-6900 Fax: 812-355-6912 | |
Dr. Jason Kasza, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 550 S Landmark Ave, Bloomington, IN 47403 Phone: 812-355-2750 Fax: 812-355-2751 | |
Dr. Lindita N Coku, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2651 E Discovery Pkwy, Bloomington, IN 47408 Phone: 812-334-5081 Fax: 812-334-5091 | |
Mr. Charles R. Mckeen Iii, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 421 W 1st St, Bloomington, IN 47403 Phone: 812-332-3531 Fax: 812-332-4673 | |
Dr. Raghunandan Lakshmana Motaganahalli, Surgery Medicare: Accepting Medicare Assignments Practice Location: 2651 E Discovery Pkwy, Bloomington, IN 47408 Phone: 812-355-6900 Fax: 812-339-1292 |